Hyperfine (HYPR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Apr, 2026Executive summary
Annual meeting scheduled for May 21, 2026, to be held virtually via live audio webcast.
Shareholders are encouraged to review proxy materials and vote by May 20, 2026.
Voting matters and shareholder proposals
Election of five directors: Daniel J. Wolterman, Maria Sainz, John Dahldorf, Ruth Fattori, and Jonathan M. Rothberg, Ph.D.
Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and the auditor ratification.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Hyperfine
- Director elections, auditor ratification, and executive pay updates under controlled company governance.HYPR
Proxy filing14 Apr 2026 - Q4 2025 revenue up 128% year-over-year; 2026 guidance targets 55% growth and margin gains.HYPR
Q4 202519 Mar 2026 - Record Q2 revenue, raised 2024 guidance, and global expansion signal accelerating growth.HYPR
Q2 20242 Feb 2026 - Portable AI-powered brain MRI drives growth and expands access in neurology care.HYPR
Jefferies Global Healthcare Conference1 Feb 2026 - Portable brain MRI drives clinical and financial growth, targeting stroke and Alzheimer's markets.HYPR
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - AI-powered portable MRI drives growth, access, and efficiency in brain imaging markets.HYPR
Investor presentation20 Jan 2026 - Q3 revenue up 56% with record margins; global expansion and AI innovation fuel growth.HYPR
Q3 202414 Jan 2026 - 2024 revenue up 17%, margins improved, and 2025 guidance targets 20–30% growth.HYPR
Q4 202426 Dec 2025 - AI-powered portable brain MRI drives rapid growth and global expansion, with strong Q3 results.HYPR
Piper Sandler 37th Annual Healthcare Conference7 Dec 2025